UBS Initiates Esperion Therapeutics With Buy

Analysts at UBS initiated coverage on

with a Buy rating. The target price for Esperion Therapeutics is set to $140. Esperion Therapeutics shares have gained 525.68% over the past 52 weeks, while the S&P 500 index has surged 9.36% in the same period. Esperion Therapeutics' shares rose 4.21% to $96.50 in pre-market trading.